Guardant Health (NASDAQ:GH)‘s stock had its “outperform” rating reissued by research analysts at William Blair in a research report issued to clients and investors on Friday, Zacks.com reports.
Several other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Guardant Health from a “buy” rating to a “hold” rating in a research note on Thursday. ValuEngine raised shares of Guardant Health from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Canaccord Genuity reissued a “buy” rating and set a $125.00 price target on shares of Guardant Health in a research note on Friday. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Cowen set a $110.00 price target on shares of Guardant Health and gave the stock a “buy” rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $104.40.
Shares of Guardant Health stock opened at $71.89 on Friday. Guardant Health has a 1 year low of $31.06 and a 1 year high of $112.21. The firm has a market cap of $6.32 billion and a PE ratio of -25.68. The company has a 50 day simple moving average of $66.52 and a two-hundred day simple moving average of $80.32.
In related news, CEO Helmy Eltoukhy sold 426,301 shares of Guardant Health stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $99.58, for a total value of $42,451,053.58. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Richard B. Lanman sold 5,764 shares of Guardant Health stock in a transaction on Friday, November 1st. The stock was sold at an average price of $67.99, for a total transaction of $391,894.36. Insiders have sold 5,883,465 shares of company stock worth $474,143,453 over the last three months. Insiders own 13.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Advantage Investment Management LLC increased its position in Guardant Health by 200.0% during the 2nd quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock valued at $39,000 after purchasing an additional 300 shares during the period. HM Payson & Co. purchased a new position in Guardant Health during the 2nd quarter valued at $43,000. Oppenheimer Asset Management Inc. purchased a new position in Guardant Health during the 2nd quarter valued at $62,000. Whittier Trust Co. purchased a new position in Guardant Health during the 3rd quarter valued at $62,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Guardant Health during the 2nd quarter valued at $76,000. 79.18% of the stock is currently owned by institutional investors.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Read More: What is a back-end load?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.